Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bacil PharmaBOM:524516 -4.99%33 PB Ratio is 0.98 as of Aug. 08, 2026. GuruFocus rates BOM:524516 with a GF Score™ of 33/100. Among 921 Drug Manufacturers companies, Bacil Pharma ranks better than 69.49% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-08-08), Bacil Pharma's share price is ₹16.93. Bacil Pharma's Book Value per Share for the quarter that ended in Mar. 2026 was ₹17.29. Hence, Bacil Pharma's PB Ratio of today is 0.98.
The historical rank and industry rank for Bacil Pharma's PB Ratio or its related term are showing as below:
BOM:524516'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 1.63
Current: 1.14
During the past 13 years, Bacil Pharma's highest PB Ratio was 1.63. The lowest was 0.00. And the median was 0.00.
BOM:524516's PB Ratio is ranked better than 69.49% of 921
companies
in the Drug Manufacturers industry
Industry Median: 1.96
vs BOM:524516: 1.14
During the past 12 months, Bacil Pharma's average Book Value Per Share Growth Rate was -2.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 110.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 60.10% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 1.10% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Bacil Pharma was 110.00% per year. The lowest was -40.00% per year. And the median was -2.80% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Bacil Pharma PB Ratio Related Terms
Bacil Pharma PB Ratio Historical Data
* Premium members only.
The historical data trend for Bacil Pharma's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bacil Pharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bacil Pharma PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bacil Pharma's PB Ratio distribution charts can be found below:
* The bar in red indicates where Bacil Pharma's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Bacil Pharma's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Bacil Pharma (BOM:524516) has a PB Ratio of 0.98 as of Aug. 08, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Bacil Pharma and its competitors. According to the industry distribution chart, Bacil Pharma ranks #281 out of 921 companies in the Drug Manufacturers industry, placing it in the top 30.5%.
Is Bacil Pharma's PB Ratio too high?
Bacil Pharma's current PB Ratio is 0.98. The Drug Manufacturers industry median PB Ratio is 1.96. Bacil Pharma's value of 0.98 is 50% below this industry median. Based on the distribution chart, Bacil Pharma ranks #281 out of 921 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Bacil Pharma has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Bacil Pharma's PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Bacil Pharma ranks #281 out of 921 companies for PB Ratio. This puts Bacil Pharma in the upper half of its industry. The industry median PB Ratio is 1.96. Bacil Pharma's value of 0.98 is 50% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.96, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bacil Pharma's current PB Ratio of 0.98 is 50% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Bacil Pharma and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bacil Pharma's current PB Ratio is 0.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bacil Pharma stock overvalued right now?
Bacil Pharma (BOM:524516) has a current PB Ratio of 0.98. The current PB Ratio is 0.98 and 50% below the Drug Manufacturers industry median of 1.96. Bacil Pharma's overall GF Score™ is 33/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Bacil Pharma (BOM:524516), the current PB Ratio is 0.98 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bacil Pharma Ltd is an Indian-based pharmaceutical company engaged in healthcare solutions, basically in the development, manufacturing, and distribution of a range of pharmaceutical products across therapeutic segments. operating in a single segment. The product of the company includes tablets, capsules, injectables, ointments, and specialty products.
33GF Score
Get the complete analysis for BOM:524516
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524516 has been successfully added to your 
